Business Wire

OWL-LABS

23.6.2021 01:03:07 CEST | Business Wire | Press release

Share
Owl Labs: 89% of European Companies Plan on Having a Hybrid Workforce Post-pandemic

Research conducted by Owl Labs , which polled 2000 business leaders* based in the UK, Germany, France, and the Nordics** shows that just 11% of business leaders expect their employees to return to the office full-time, indicating a more permanent shift to hybrid working. What’s more, the majority of European organisations (92%) are keen to explore progressive policies post-pandemic including introducing working from anywhere (42%), core working hours (39%), a four-day week (39%), and unlimited holiday (22%). When considering why employers are permanently moving to a more flexible work model, profitability plays an important role. Close to two-thirds (62%) of European business leaders reported that hybrid working makes companies more profitable with Enterprise businesses (1000+ employees) the most likely to think so (73%) versus small and medium-sized companies (55%).

As businesses continue to adapt to working in a Covid-19 environment, over a third (39%) of European business leaders anticipate that Covid-19 will continue to impact the running of their business for up to six months. French business leaders are the most optimistic with one in five (20%) believing Covid-19 would only impact the running of their office for the next three months or less. However, the majority believe that remote and hybrid working has positively impacted their business, with the majority stating it had impacted employee wellbeing (52%) and business costs (50%) positively.

With a growing desire to support employees' partial return-to-office, one in four EU organisations (24%) are now planning to enforce ‘vaccine passports’ and only allow those who have been vaccinated into the office. Germany is the most cautious with 31% of business leaders insisting on Covid-19 vaccines, while 23% of business leaders in the UK, 21% in the Nordics and 19% in France intend to enforce vaccines. Additionally, over a third (38%) of EU business leaders are considering providing onsite Covid-19 testing facilities to encourage employees to return to work, with French and German organisations most likely to provide onsite testing facilities at 42% and 43% respectively.

European organisations are already planning ahead to a post-pandemic work environment, with the majority of business leaders (63%) aiming to maintain the same amount of office space, even with the rise of hybrid work. Just 11% are planning to get rid of their offices entirely (rising to 14% in the Nordics). When it comes to hiring, one-third of EU organisations (32%) plan to hire employees who can work remotely, based on skill, rather than their proximity to an office. In a move that may not be welcomed by employees, 29% of business leaders plan to use productivity apps to monitor activity of remote employees. This rises steeply in Germany, where 37% of business leaders plan on utilising productivity and activity monitoring of remote employees, compared to just 22% of Nordic business leaders.

As businesses move to hybrid and flexible working, technology plays a crucial role in enabling this shift. As a result, the majority (93%) of European organisations are putting workplace policies and infrastructure in place to prepare for a post-pandemic workplace. This includes nearly half (42%) of European businesses investing in new tech and solutions to support a hybrid workforce. The UK leads the tech charge with 43% investing in communications tools (such as Slack, Zoom, and Meeting Owl conference cameras) compared to 28% in the Nordics, 36% in France and 38% in Germany. The primary activities companies are carrying out to prepare their workplaces now and post-pandemic are:

○ Investing in communication tools and technology (Slack, Zoom, conference cameras, Meeting Owls, etc.) (36%)

○ Continued social-distancing measures for employees in the office (35%)

○ Providing at-home and in-office equipment for employees so they can easily work from both locations (33%)

Frank Weishaupt, CEO of Owl Labs says, “It’s encouraging to see business leaders across Europe embrace hybrid work post-pandemic. As organisations have adapted to working remotely, they’ve seen the benefits. The ability to hire remote teams from anywhere, leverage new technologies whilst saving on costs. We know that technology will continue to play a key role in supporting this permanent shift to hybrid work, and businesses that will be successful will create the infrastructure and workplace policies that enable their employees to maintain high levels of creativity and collaboration, wherever they dial-in from.”

---ends---

Methodology:

* Business Leaders refer to C-suite executives, heads of departments, HR managers and general managers

**The Nordics refers to Sweden, Finland, Norway & Denmark

About Owl Labs

Owl Labs is a collaborative technology company dedicated to creating a better workplace and learning experience for today's hybrid workforce and virtual classroom. The company’s flagship product, the award-winning Meeting Owl Pro , features a wifi-enabled, portable 360° camera, mic, and speaker with proprietary AI technology that automatically focuses on who is speaking using audio and visual cues. The company is a recipient of TIME’s Best Inventions of 2020 and is dedicated to providing collaborative and productivity solutions for organizations to stay connected to their remote employees and educators to stay connected to their remote students, regardless of location. Learn more at www.owllabs.com .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 22:04:00 CEST | Press release

- Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex’s portfolio - - PALSONIFY®, Crinetics’ recently launched, first and only, once-daily oral therapy for adults with acromegaly has demonstrated strong and growing early uptake - - Atumelnant, a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist in Phase 3 development for congenital adrenal hyperplasia (CAH), has shown unique and transformative potential to both normalize androgen levels and enable management of patients with physiologic levels of glucocorticoids, the true goal of CAH management; atumelnant has also demonstrated therapeutic potential in patients with Cushing’s syndrome - - Acquisition adds to Vertex’s innovation pipeline, accelerates Vertex’s revenue growth and enhances long-term earnings profile - - Vertex to host investor call today, July 6 at 4:30 p.m. ET - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and C

Ciauru Wins the Second Edition of the Reply AI Music Contest, the International Competition Dedicated to Experimentation Across AI, Music and Live Performance6.7.2026 20:30:00 CEST | Press release

The winner was announced on the Kappa FuturFestival stage, following the performances of the five finalists selected by the international jury.German duo PARAFRAME & Avis Vox received the special Reply AI Studios Grand Prix award. The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706007611/en/ The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival First place went to Ciauru, the stag

Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 15:00:00 CEST | Press release

Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda

Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 15:00:00 CEST | Press release

Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm

No-Loss Trading Platform UpsideOnly Surpasses 100,000 Users Within Weeks of Launch6.7.2026 14:48:00 CEST | Press release

Rapid growth shows strong demand for a new trading model where users can make market predictions without risking their own capital Perpetuals.com Ltd (Nasdaq: PDC), today announced that UpsideOnly, its risk-free trading and market prediction platform, has seen a surge in new user sign-ups, surpassing the important milestone of 100,000 traders within weeks of its launch on May 19. UpsideOnly lets users make predictions about where global equity, commodity, forex, and crypto markets are heading without ever placing a real trade themselves. Perpetuals uses its own capital to trade on the strongest signals identified by its proprietary AI. If those trades win, Perpetuals shares the profits with the users who helped generate the signal. If the trade doesn’t make money, users lose nothing. Reaching 100,000 users so quickly after launching is a reflection of the enormous demand for a platform that flips the traditional retail trading model on its head, with early platform data showing strong

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye